Gain Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

GANX$1.08-0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS


· September 30, · December 31,
· · · 2024 · · 2023
Assets · ·
Current assets: · ·
Cash and cash equivalents	$12,049,522	$11,794,949
Marketable securities - current	—	4,999,704
Tax credits	373,726	242,577
Prepaid expenses and other current assets	1,318,092	741,638
Total current assets	$13,741,340	$17,778,868

Non-current assets:
Property and equipment, net	$119,610	$125,962
Internal-use software	156,256	193,375
Operating lease - right of use assets	281,578	459,215
Restricted cash	33,873	34,021
Long-term deposits and other non-current assets	33,007	17,890
Total non-current assets	624,324	830,463
Total assets	$14,365,664	$18,609,331

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$1,098,453	$1,318,965
Operating lease liability - current	178,781	229,693
Other current liabilities	2,491,254	2,160,366
Deferred income - current	708,027	1,122,138
Loans - current	118,280	118,797
Total current liabilities	$4,594,795	$4,949,959

Non-current liabilities:
Defined benefit pension plan	$323,266	$307,454
Operating lease liability - non-current	96,222	229,855
Deferred income - non-current	65,869	94,786
Loans - non-current	376,130	449,053
Total non-current liabilities	861,487	1,081,148
Total liabilities	$5,456,282	$6,031,107

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of September 30, 2024 and December 31, 2023.	—	—
Common stock, $0.0001 par value: 50,000,000 shares authorized; 25,962,246 issued and outstanding as of September 30, 2024; 16,206,680 issued and outstanding as of December 31, 2023.	2,596	1,621
Additional paid-in capital	86,090,657	73,113,079
Accumulated other comprehensive income	242,810	247,241
Accumulated deficit	(60,783,717)	(38,516,197)
Loss for the period	(16,642,964)	(22,267,520)
Total stockholders’ equity	8,909,382	12,578,224
Total liabilities and stockholders’ equity	$14,365,664	$18,609,331

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.